Months after axing a Duchenne program and laying off dozens, Santhera claims a win there with a different program

Last fall, Santhera Pharmaceuticals unceremoniously dumped a Duchenne program after it flunked a Phase III trial, forcing a wave of layoffs that trimmed the biotech’s staff from 120 to 40. Now, the Swiss company believes it’s found a path to a comeback with a different candidate in Duchenne.